Kara Norman

Postdoctoral Fellow
Ph.D. Microbiology and Infectious Diseases and Cancer Biology, University of Calgary. Calgary, AB. Canada.
B.Sc. (Hons) Cellular, Molecular and Microbial Biology. University of Calgary. Calgary, AB. Canada.

 

Fellowship
Alberta Heritage Foundation for Medical Research Postdoctoral Fellowship

 

Project
Cellular targets of miR-122 and implications for Hepatitis C virus replication

 

Publications
Norman KL, PW Lee. (2000) Reovirus as a novel oncolytic agent. J. Clin. Invest. 105: 1035-1038. [Link]

Norman KL, Farassati F and PW Lee. (2001) Oncolytic viruses and cancer therapy. Cytokine and Growth Factor Rev. 12: 271-282. [Link]

Norman KL, PW Lee. (2001) Reovirus as a potential anticancer therapeutic. In Replication-competent Viruses for Cancer Therapy. Hernaiz-Driever P and SD Rabkin, Eds. p.81-99.

Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW. (2002) Oncolytic reovirus against ovarian and colon cancer. Cancer Res. 62: 1696-1701. [Link]

Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, Strong JE, Lee PW. (2002) Reovirus oncolysis of human breast cancer. Hum. Gene Ther. 13: 641-652. [Link]

Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, Waisman DM, Lee PW. (2003) Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res. 63: 348-353. [Link]

Patrick M, Norman KL, PW Lee. (2003) Reovirus as an Oncolytic Agent. In Cancer Gene Therapy. DT Curiel and JT Douglas, Eds. Humana Press, Inc.

Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW. (2004) Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc. Natl. Acad. Sci. U S A. 101: 11099-11104. [Link]

Yang WQ, Senger DL, Lun XQ, Muzik H, Shi ZQ, Dyck RH, Norman K, Brasher PM, Rewcastle NB, George D, Stewart D, Lee PW, Forsyth PA. (2004) Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Ther. 11: 1579-1589. [Link]

Loken SD, Norman K, Hirasawa K, Nodwell M, Lester WM, Demetrick DJ. (2004) Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anti-cancer biotherapeutic. Cancer Biol. Ther. 3: 734-738. [Link]

Norman KL, Lee PW. (2005) Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov. Today. 10: 847-855. [Link]

Sarnow P, Jopling CL, Norman KL, Schütz S, Wehner KA. (2006) MicroRNAs: expression, avoidance and subversion by vertebrate viruses. Nat. Rev. Microbiol. 4: 651-659. [Link]

Jopling CL, Norman KL, Sarnow P. (2006) Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122. Cold Spring Harb. Symp. Quant. Biol. 71: 369-376. [Link]

Norman KL, Sarnow P. (2010) Modulation of hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR-122 involves distinct mechanisms. J. Virol. 84(1):666-670. [Link]

Zeiner GM, Norman KL, Thomson JM, Hammond SM, Boothroyd JC. Toxoplasma gondii infection specifically increases the levels of key host microRNAs. (2010) PLoS One. 2010 Jan 15;5(1):e8742. [Link]


Stanford University Home Page